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Abstract 
Cardiovascular diseases represent the first cause of death in the Western World as current therapies 
are often only palliative. As a consequence, today, heart transplantation is essentially still the only 
possible choice for many patients. However, several novel therapeutic approaches have been 
attempted in the past two decades, with quite encouraging results. Along this line, generation of 
induced pluripotent stem cells, through the forced expression of stem-cell specific transcription 
factors, inspired the most recent and attractive strategies for heart regeneration, consisting in the 
direct reprogramming of cardiac fibroblasts into functional cardiomyocytes. First attempts were 
conducted using a similar approach than the one used with transcription factors, but during years, 
novel strategies have been tested, e.g. miRNAs, recombinant proteins and chemical molecules. 
Although preliminary results on animal models are promising, the low reprogramming efficiency as 
well as the incomplete maturation of the cardiomyocytes still represent important obstacles before a 
clinical translation could be foreseen.  
This review covers all the different direct transdifferentiation strategies that have been proposed and 
developed, illustrating the pros and cons of each approach. Indeed, as described in the manuscript, 
there are still many unanswered questions and drawbacks that require a better understanding of the 
basic signaling pathways and transcription factor networks before functional cells, suitable for 
cardiac regeneration and safe for the patients, can be generated and used for human therapies. 
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1. Introduction 
The latest annual World Health Statistic report of the World Health Organization (WHO, June 
2016) indicates the cardiovascular diseases as the leading cause of death worldwide, resulting in 
17.7 million deaths in 2015 alone and, despite new medical advances, the number is expected to 
grow to more than 23.6 million per year by 2030. Thus, it is quite clear that the cardiovascular 
diseases represent an enormous problem for the modern society, also from an economic perspective, 
with a cost for the world healthcare system estimated to be about 860 billions of dollars per year 
(http://www.who.int/en).  Therefore, the development of novel, efficient, and cost-effective cardiac 
therapies is a fundamental goal that is evoked worldwide. Actually, it is well known that most of the 
heart diseases are often accompanied by a severe loss of cardiomyocytes (CMs) and by a 
pathological remodeling of the heart, culminating in heart failure or even sudden death [18]. As a 
matter of fact, one of the main problems to be addressed resides in the very limited regenerative 
capacity of the adult human heart. For instance, after a myocardial infarction, the injured area is 
replaced by a fibrotic scar, that on one side is able to protect the heart wall from rupturing, but on 
the other side, unfortunately, it is unable to contract and to conduct electrical signals, ultimately 
resulting in an elevated stress for the heart, which irredeemably affects cardiac performance [45]. 
As a consequence, nowadays, heart transplantation is essentially the only possible treatment for 
these patients. Clearly, this therapeutic approach is impracticable on a large scale, because of the 
shortage of heart donors, without considering the lifetime immunosuppressant therapy required 
after transplantation [53]. Thus, alternative regenerative therapies are extremely needed, and great 
attention has been focused in the past two decades on stem cell-based approaches, using different 
cell sources, including embryonic stem cells (ESCs), mesenchymal stem cells (MSCs), induced 
pluripotent stem cells (iPSCs), and cardiac stem cells (CSCs). Although several clinical trials with 
adult stem cells have now reached Phase II and III, no approach stands out, and searching for the 
“ideal” stem cell to be used, if it even exists, is still ongoing, as extensively reviewed in the 
literature [5, 14, 35, 42]. On the other hand, more recently, an alternative approach has been 
proposed, which is the possibility of directly reprogramming cardiac fibroblasts into 
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cardiomyocytes, without the need of isolating and re-injecting the stem cells. Ideally, with this 
approach, the scar tissue of a damaged myocardium could be reverted into functional cardiac 
muscle. This novel concept for heart regeneration is quite fascinating yet very challenging, and over 
the past few years it has been tackled in different ways. Thus, the main aim of this review is to 
describe all the direct reprogramming strategies available, highlighting the pros and cons of each 
approach, in order to have the most unbiased picture of where we are now and where we are 
heading to. 
 
2. Direct Cardiac Reprogramming 
The idea of directly reprogramming (or trans-differentiating) an adult and differentiated cell into 
another fully mature type is truly not so novel, as the first attempt of a direct conversion was 
performed back in 1987. In fact, it was demonstrated that the forced expression of the muscle-
specific transcription factor MyoD induced myogenic features in mouse fibroblasts by activating the 
target cell program, and concomitantly repressing the starting cell transcriptional profile [12]. 
However, it was only the generation of iPSCs in 2006 by Yamanaka and colleagues that really built 
the scientific basis for alternative reprogramming strategies [54, 55]. In fact, soon after Yamanaka’s 
discovery, the idea of a direct conversion of terminally differentiated cell types into different ones, 
without passing through the pluripotent stage, started to emerge. In particular, the overexpression of 
specific transcription factors and/or microRNAs allowed the direct conversion of fibroblasts into 
several different cell lineages, including pancreatic  cells [67], neurons [59], and hepatocyte-like 
cells [20]. However, it soon became clear that obtaining functional cardiomyocytes directly from 
fibroblasts was going to be more cumbersome than expected, mainly because of the heterogeneity 
and complexity of the heart tissue. Indeed, in the human heart, 30% of cells are cardiomyocytes, 
whereas 70% are represented by several “non-myocyte” cells, the majority of which being different 
subtypes of cardiac fibroblasts [27]. These types of fibroblasts, which are known to express several 
cardiac-specific genes like GATA4, play a crucial role after myocardial injury, as they become 
active myofibroblasts, migrate to injured zones, and create a non-contractile scar that eventually 
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impairs cardiac functionality [39]. On the other hand, cardiac fibroblasts seem to originate from the 
same common progenitor as the CMs [58], thus they were soon selected as the “optimal” cell type to 
be reprogrammed into CMs.  
In the past ten years, three main different classes of reprogramming strategies have been developed, 
which are divided according to the method used to obtain the fibroblast conversion: (a) purely 
genetical, (b) a mix of a genetical and a chemical approach, and (c) only chemical. In the next 
sections, each approach will be described and discussed in detail. 
 
2.1. Genetical Direct Cardiac Reprogramming 
Soon after the seminal discovery that the forced expression of four genes (SOX2, KLF4, c-MYC, 
OCT4) could reprogram fibroblasts into iPSCs [55], researchers have hypothesized that, with a 
similar approach, adult cells could be reprogrammed into other types of differentiated cells [67]. 
Thus, in the field of heart regeneration, efforts have been made toward the unveiling of the “master 
regulators” of cardiac differentiation by analyzing the transcriptional regulation machinery of the 
developing heart [44, 52]. In particular, it was soon demonstrated that two cardiac transcription 
factors, GATA4 and TBX5, in combination with BAF60c, a cardiac-specific subunit of the BAF 
chromatin remodeling complex, could induce the formation of ectopic beating cardiomyocytes in 
mesodermal cells of early mouse embryos, including the normally not cardiogenic posterior 
mesoderm, and the extraembryonic mesoderm of the amnion, but not in adult cells [56]. In 2010, 
Ieda and colleagues reported the first successful reprogramming experiments of mouse fibroblasts 
into functional CMs, hereafter defined induced cardiomyocytes (iCMs), and identified a pool of 14 
transcription factors that exhibited severe developmental cardiac defects when mutated [21]. Upon 
transduction with a mixture of these factors, they obtained cell expressing cardiac MHC. Then, 
using a single-factor-elimination strategy, they defined the combination of three critical genes, 
Gata4, Mef2c, and Tbx5 (the GMT cocktail), that were sufficient to reprogram mouse fibroblasts 
into iCMs after one week in culture. After retroviral/lentiviral transduction, the “GMT cocktail” 
was able to induce the direct conversion of cardiac and dermal post-natal murine fibroblasts in 
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functional CMs, expressing cardiac troponin T and with a general gene expression profile similar to 
neonatal CMs. Moreover, 30% of iCMs derived from cardiac fibroblasts showed spontaneous Ca
2+
 
oscillations with a variable frequency and, above all, they had spontaneous contractile activity. 
Remarkably, the reprogramming process occurred through the generation of a cardiac precursor-
like stage without an intermediate pluripotent state, as suggested by the low expression levels of the 
pluripotency genes such as Oct4, Sox2, Nanog and Klf4. However, the efficiency was generally low 
and beating cells could be observed only in iCMs derived from cardiac fibroblasts [21]. However, 
along this line, other groups obtained quite unsuccessful results with the GMT combination, 
supporting the idea that GMT factors alone were inefficient to completely convert fibroblasts into 
CMs, but rather produced partially reprogrammed cell types [8, 47]. Thus, several studies were 
performed to improve the efficiency of the reprogramming process, modifying the original GMT 
set, adding or substituting some transcription factors. For example, Proetze and colleagues directly 
screened all possible triplet combinations starting from ten candidate genes, eventually unveiling 
that, by combining Myocd, instead of Gata4, with Tbx5 and Mef2c, significantly increased neonatal 
cardiac fibroblasts reprogramming efficiency, generating iCMs characterized by the expression of 
cardiac contractile proteins and by potassium/sodium currents typical of cardiac cells. 
Unfortunately, no beating cells were observed, possibly because the trans-differentiation into 
functional CMs was incomplete [47]. Concurrently, Olson’s group developed another 
reprogramming strategy, adding Hand2 to GMT, that became GHMT, inducing a 20% increase in 
the fibroblast conversion efficiency [51]. Moreover, a methodical study on cell markers expression 
of different CMs subtypes, defined a multiplex immunostaining strategy to distinguish individual 
CMs subtypes. Using this screening protocol, it was observed that GHMT treatment generated 
different CMs phenotypes in similar proportions, resembling immature forms of atrial, ventricular 
and pacemaker subtypes. This evidence was further confirmed by patch clamping experiments on 
spontaneously contracting iCMs. Moreover, even if the action potential of every subtype showed 
peculiar features, many differences were highlighted between iCMs and adult CMs, indicating that 
the reprogrammed fibroblasts were not fully electrophysiologically competent and mature [40]. 
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Despite these numerous challenges and uncertain results, direct reprogramming approaches were 
tested in vivo on mice models using GMT [48] or GHMT [51] vectors. Both groups reported 
evidences that fibroblasts conversion into CMs was more efficient in vivo than in vitro. Moreover, 
since the retroviruses used to deliver GMT directly into the heart can only integrate in dividing 
cells, the reprogramming factors may affect only cardiac fibroblasts. These cells, once transformed 
into iCMs, were able to ameliorate cardiac function after myocardial injury, decreasing infarct size 
and improving cardiac parameters, such as the fractional shortening and the stroke volume. In 
particular, the analysis of the cells phenotype revealed that iCMs generated in vivo were more 
mature than the ones obtained in vitro, perhaps due to the cardiac microenvironment that could 
facilitate their differentiation [48, 51]. Moreover, it was reported that the efficacy of in vivo cardiac 
fibroblasts reprogramming could be enhanced by infarct pretreatment with pro-angiogenic and 
fibroblast activating peptides, such as Thymosin β4 [51] or vascular endothelial growth factor 
(VEGF) [33]. Both treatments resulted in fibrosis reduction and in cardiac function improvement. 
More recently, a novel strategy for cardiac reprogramming of fibroblasts into iCMs has been 
introduced, and it is based on the use of a polycistronic vector to transduce target cells, instead of 
all single constructs. In particular, supported by the positive results achieved in iPSCs generation 
[65], Inagawa and colleagues applied the same approach for cardiac reprogramming, using a 
polycistronic retrovirus expressing GMT. Unfortunately, they obtained only marginal positive 
effects in fibroblasts conversion into iCMs, as compared to the single vector strategy [23]. 
Surprisingly, the optimal balance among the transcriptional factors emerged as a crucial point for 
the reprogramming efficiency [62]. In particular, polycistronic vectors with all the possible 
combinations of the G-M-T factors were generated and tested. The combination that gave the 
highest MEF2C protein levels, the M-G-T vector, improved by ten folds the reprogramming 
efficiency as compared to the original GMT set. CMs obtained with this approach showed a more 
mature phenotype, characterized by the expression of Connexin43, the protein of the gap junctions, 
and by the sarcomeric structures typical of fetal CMs and by Ca
2+
 periodic oscillations. 
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Unfortunately, switching from mouse to human cells was all but straightforward, as several 
attempts with the GMT combination failed [16, 41, 60]. Thus, researchers had to go back from 
scratch to search for a new combination of factors. After many attempts, they eventually fairly 
succeeded using a new complex “cocktail” that was identified from fourteen transcriptional factors 
known to be crucial during heart development, and three muscle-specific miRNAs [41]. Thus, the 
transduction of a combination composed by GATA4, TBX5, HAND2, MEF2C, MYOCARDIN, miR-
1, and miR-133 was sufficient to obtain 20% of troponin T positive cells from neonatal human 
foreskin fibroblasts, but only rare beating foci after a long period of culture [41]. Moreover, the 
conversion efficiency markedly decreased when using adult cardiac or dermal fibroblasts, possibly 
because adult cells own a more stable epigenetic state which counteract the reprogramming process 
[41]. Many other attempts have been conducted to improve this conversion by modifying the 
transcription factors combination. However, the reprogramming process was still characterized by a 
general low efficiency [16, 38, 60]. 
An alternative strategy to obtain iCMs without the use of transcription factors was reported by 
Jayawardena and colleagues, who employed miRNAs [25]. They identified six miRNAs important 
for cardiac muscle development and differentiation and, by a combinatorial strategy, they tested 41 
different combinations of two or three miRNAs. The combination of miR-1, miR-133, miR-208 and 
miR-499 was able to induce the direct transdifferentiation of transiently transfected murine 
fibroblasts into iCMs expressing specific cardiac proteins and showing sarcomeric structures and 
calcium fluxes [25]. More recently, the same group tested the potential of their miRNAs cocktail to 
induce fibroblast reprogramming directly in vivo [26]. The intramyocardial delivery of the miRNAs 
generated iCMs resembling mature ventricular CMs for many characteristics, especially regarding 
the action potential. Moreover, miRNAs iCMs ameliorated the fractional shortening, decreased the 
left ventricular mass and reduced the grade of fibrosis, finally promoting the functional recovery of 
the damaged myocardium [26].  
The genetical direct cardiac reprogramming described approaches are summarized in Table 1. 
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2.2. Genetical/Chemical Direct Cardiac Reprogramming 
A different approach for fibroblasts transdifferentiation into CMs was proposed by Efe and 
colleagues, the so-called Cell-Activation and Signaling-Directed (CASD) Lineage Conversion 
Method [13]. The new approach consists in exposing the cells to be reprogrammed to an initial 
epigenetic activation phase, which is meant to facilitate the successive differentiation toward the 
cardiac phenotype, using a chemically defined cardiogenic medium. In particular, cell activation 
was obtained overexpressing Oct4, Sox2 and Klf4, three of the reprogramming genes established in 
the standard iPSCs generation protocol [55], and maintaining the cells in feeder-free culturing 
conditions without leukemia inhibitory factor (reprogramming medium) to avoid the generation of 
pluripotent cells [13]. During the first nine days of treatment, mouse embryonic fibroblasts, 
transduced with the three factors, were continuously maintained in the reprogramming medium in 
the presence of the JAK inhibitor JI1, and then shifted for five days to the cardio-inductive medium 
supplemented with BMP4. Following this approach, it was possible to observe an up-regulation of 
mid-stage cardiac markers, such as Flk-1, Gata4 and Nkx2.5, starting from day ten, whereas, from 
day eleven onwards, the expression of late-stage markers including Troponin T, -MHC and -
actinin resulted increased. Moreover, many converted fibroblasts started to express the gap 
junctions’ protein Connexin43, and simultaneously several colonies showed spontaneous waves of 
contractions. Interestingly, the obtained iCMs expressed only the atrial isoform of the myosin light 
chain (MLC-2a), suggesting that the reprogrammed fibroblasts principally acquired the atrial 
phenotype [13].  
The relevance of the CASD approach was confirmed by other independent studies, where the 
method was used to generate several cell subtypes, including neural [68], endothelial [28] and 
pancreatic cells [29], in all cases without going through the induction of a pluripotent state. 
However, the CASD approach requires a genetic manipulation step, that rises questions about safety 
and efficiency, in the perspective of a possible clinical translation of this strategy. Indeed, many 
research groups are persuaded that eliminating all genetic factors in the reprogramming process 
represents a fundamental step for the development of a safe therapeutic approach. Along this line, 
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the first attempt to reduce, at least partially, the genetic manipulation in cardiac reprogramming was 
performed by Wang and colleagues [61]. Starting from the established CASD approach [13], they 
screened small molecules that could replace the pluripotency transcription factors to activate mouse 
fibroblasts and convert them into CMs. Combining iPSCs inducing/enhancing small molecules 
together with cardiogenic small molecules to activate the cells and then to direct the differentiation 
process toward the cardiac phenotype, they defined a cocktail of compounds consisting of 
SB431542 (ALK4/5/7 inhibitor), CHIR99021 (GSK3 inhibitor), parnate (LSD1/KDM1 inhibitor), 
and forskolin (adenylyl cyclase activator) (SCPF), which was sufficient to convert mouse 
embryonic fibroblasts (MEFs) or mouse tail-tip fibroblasts (TTFs) into iCMs in combination with 
only one pluripotency transcription factor (Oct4) [61, 68]. In particular, converted cells expressed 
cardiac-specific genes, such as Myh6, TnnT2, Ryr2, Gata4, Nkx2.5, and the first beating cluster 
appeared around day twenty after treatment. Interestingly, immunostaining analysis revealed the 
presence of the myosin light chain-2v (MLC2v), which is a ventricular specific marker, indicating 
that most of the iCMs were of the ventricular subtype, as confirmed also by the action potential 
measurements [61]. Since ventricular cardiomyocytes are the cell population that is typically lost 
during myocardial infarction, the results obtained by this modified CASD approach could represent 
the basis for a considerable step forward in the bench to bed translational process of direct cardiac 
reprogramming strategies. 
The combination of the genetic and chemistry characteristics of the CASD approach was applied 
also with the more “classical” cardiac transcription factors cocktail (GMT). In fact, several studies 
demonstrated that reprogramming efficiency of genetical reprogramming could be increased with 
the use of small molecules to induce or inhibit specific molecular pathways. In particular, it was 
demonstrated that, during GHMT reprogramming, suppression of pro-fibrotic signaling by TGF- 
inhibitors SB431542 or A-8301, or by ROCK inhibitor Y-27632 increased the conversion 
efficiency 5-fold in both embryonic and adult mouse fibroblasts [22], and enhanced the kinetics of 
the reprogramming process, with spontaneously contracting CMs emerging in less than two, instead 
of four, weeks [66]. The group of Yamakawa [63] screened eight cardiogenic compounds used to 
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differentiate pluripotent stem cells in combination with GMT cocktail. They found that the 
combination of fibroblast growth factor 2 (FGF2), FGF10, and VEGF, greatly improved the quality 
of cardiac reprogramming of mouse fibroblasts, activating p38 mitogen-activated protein kinase and 
phosphoinositol 3-kinase/AKT pathways and also removing Gata4. A screening of 5,500 
compounds in GMT-overexpressing murine fibroblasts, identified two molecules (the TGF- 
inhibitors SB431542 and the WNT inhibitor XAV939) that increased the reprogramming efficiency 
by eight folds, reducing also the time of transdifferentiation. In vivo, the heart treated with GMT 
and molecules, showed a significant improvement after infarction, as compared to a heart exposed 
to GMT alone. It was also demonstrated that this reprogramming protocol ameliorated the 
transdifferentiation of human fibroblasts [36]. Modulation of other pathways showed an increase in 
the efficiency of fibroblast reprogramming [1]. In particular, the inhibition of the Notch pathway 
with the N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), doubled 
the conversion of mouse fibroblasts with the GMHT cocktail, increasing the binding of MEF2C to 
the promoter regions of cardiac structural genes [1]. These studies demonstrated the importance and 
the potential of small compounds in controlling and promoting the differentiation process. 
The described genetical/chemical direct cardiac reprogramming approaches are summarized in 
Table 2. 
 
2.3. Chemical Direct Cardiac Reprogramming 
As mentioned before, a purely chemical approach for direct reprogramming could intrinsically be 
safer than the genetic one. Along this line, a series of very recent studies reported the direct 
conversion of mouse and human fibroblasts into CMs without the use of viruses. In particular, 
several groups tried to directly convert fibroblasts to CMs by simply delivering specific 
transcription factors inside the cell, avoiding the use of viral vectors and exogenous DNA 
integration. Because proteins with high molecular weight cannot easily pass through the cell 
membrane, different delivery methods have been used to introduce these transcription factors inside 
the cell to induce the reprogramming process. The first attempt to transdifferentiate fibroblasts to 
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cardiomyocytes using recombinant proteins was made by Islas and colleagues in 2012 [24]. They 
showed that the combination of Mesoderm Posterior BHLH Transcription Factor 1 (MESP1), which 
is a key transcription factor in the development of cardiac mesoderm, together with the ETS Proto-
Oncogene 2 (ETS2), a transcription factor required for the mesoderm initiation from the epiblast, 
was able to convert normal human dermal fibroblasts into cardiac progenitors, expressing -striated 
actin, troponin T and troponin I. They fused MESP1 and ETS2 to a short fragment of the 
transactivator of transcription protein (TAT) to increase the cell permeability but the conversion 
efficiency still remained very low [24]. More recently, Li et al showed that individually modifying 
the four cardiac transcription factors GATA4, HAND2, MEF2C, and TBX5 (mGHMT), through a 
recently developed protein transduction reagent with high delivery efficiency and low toxicity (QQ-
reagent; US patent 2009/0298111 A1), they were able to transduce more than 96% of human 
dermal fibroblasts. In particular, combining mGHMT with a cardio-inductive medium 
supplemented with BMP4, activin A, and basic fibroblasts growth factor (bFGF), they generated 
functional human cardiac progenitor cells (piCPC) after 28 days in culture that were similar to 
cardiac progenitors in morphology, colony formation capability, expression of cardiac endogenous 
markers, and cardiac lineage differentiation potential. Moreover, mGHMT treatment was able to 
induce epigenetic modifications in the enhancer region of the cardiac progenitor-specific gene 
Nkx2.5. In fact, the enrichment of trimethylated histone H3 lysine 4 and monoacetylated histone H3 
lysine 9 proved the presence of transcriptionally active chromatin. The piCPCs were also injected 
into a rat heart tissue after myocardial infarction, and they played an important role in moderating 
the left ventricular remodeling. Thus, both ejection fraction and fractional shortening were 
improved in rats transplanted with piCPCs, together with a significant decrease in fibrosis, as 
compared to control animals at four weeks after MI [30]. 
Finally, the most recent approach for directly reprogram fibroblasts is based on the use of chemical 
cocktails of small molecules. One of the earliest evidence, even before iPSCs breakthrough, 
showing how chemistry could play a crucial role in the reprogramming strategies, was obtained 
with the synthetic purine reversine [10]. The molecule induced the de-differentiation of lineage-
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committed murine myoblasts, and reversine-reprogrammed mouse and human fibroblasts could be 
induced to differentiate into skeletal myocytes both in vitro and in vivo [4]. More recently, 
promising results were obtained by Hou and collaborators, who demonstrated the possibility to 
convert mouse somatic cells into pluripotent cells using a combination of seven small-molecules 
alone [19]. These chemically induced pluripotent stem cells (CiPSCs) [3] were very similar to ESCs 
in terms of gene expression profiles, epigenetic status and differentiation potential. Thus, treatment 
with small molecules could make exogenous transcription factors overexpression completely 
dispensable for cell fate reprogramming [19].  
Regarding CMs generation, two independent groups obtained cardiomyocytes-like cells starting 
from mouse fibroblasts with two different cocktails of small molecules. The You’s group achieved 
chemical-induced cardiomyocyte-like cells (CiCMs) selecting twelve small molecules involved in 
the induction of the reprogramming process or in the maintenance of the pluripotency of ESCs. To 
identify which combination of molecules was responsible for the generation of the spontaneously 
contracting cell population, each of the twelve small molecules was removed from the culture 
medium, and they eventually defined a combination of five small molecules (forskolin, A-8301, 
SC1, Chir99021 and BayK 8644 (FASCB)) that are sufficient to convert mouse fibroblasts into 
cardiomyocyte-like cells. In particular, these five small molecules were able to modulate different 
cellular targets such as the glycogen synthase kinase 3 (GSK-3), the activin receptor-like kinase 5 
(ALK5), the cyclic AMP [57], the ras GTPase activating protein (Ras-GAP)/extracellular signal-
regulated kinase (ERK), and calcium channels, suggesting that the reprogramming process is 
complex and mediated by several cellular signaling pathways [46]. At the same moment, Xie’s 
group identified another small molecule combination (Chir99021, RepSox, forskolin, VPA, Parnate, 
TTNPB, DZnep (CRFVPTZ)) that was able to induce murine fibroblasts conversion into chemically 
induced cardiomyocytes (CiCMs). Moreover, they showed that the combination of a four-core 
chemicals (CRFV) was sufficient to promote fibroblasts conversion. This cocktail of small 
molecules was used as the basal induction system for the screening of several compounds, including 
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modulators of cardiac development or somatic cell reprogramming, which could enhance the 
efficiency of the transdifferentiation process [17]. 
Taken together, all these chemical approaches demonstrated the possibility to convert murine 
fibroblasts into automatically beating cardiomyocyte-like cells. In both cases, the resulting CiCMs 
expressed cardiac specific markers, possessed the epigenetic status typical of cardiac genes, and 
showed the subcellular structures similar to CMs. Moreover, these cells were characterized by a 
typical cardiac calcium flux and electrophysiological features as spontaneous contractility [17, 46].  
Very recently, S. Ding’s group, a pioneer and leader in the field, for the first time successfully 
performed the chemical conversion of human fibroblasts into functional beating cardiomyocytes 
[7]. Their strategy was based on a cocktail of small molecules able to induce or enhance cellular 
reprogramming (cell activation), in combination with several cardiogenic molecules, such as activin 
A, BMP4 and VEGF, to induce their differentiation towards the cardiac cell phenotype. The pivotal 
principle of their approach, as for the other attempts discussed above, is to initially promote an 
epigenetic state in the cell to be reprogrammed, which is characterized by an open chromatin. Thus, 
cells become more responsive to stimuli with extrinsic cardiogenic factors that could bind the 
promoter/enhancer regions of key genes, modulating fundamental pathways such as TGF-β, Wnt, 
and GSK3β [31, 32]. In particular, Cao and colleagues screened several sets of compounds, in 
addition to the SCBF combination composed of SB431542, CHIR99021, parnate and forskolin. 
Finally, they optimized a cocktail composed of nine small molecules (9C) that was able to convert 
human foreskin fibroblasts into CiCMs by a sequential induction of mesoderm, cardiac progenitor 
cells, and finally cardiomyocytes, reproducing the physiological cardiogenesis [6]. CiCMs showed 
a well-organized sarcomere structure and expressed specific morphological and functional cardiac 
markers, such as cardiac troponin T and I, connexin43, atrial natriuretic factor and MLC2v. 
Moreover, 97% of these CiCMs spontaneously beat in vitro, thus demonstrating that they were 
functional and possessed electrophysiological characteristics similar to CMs. Importantly, CiCMs 
were directly reprogrammed without passing through a pluripotent cell-like state and maintained the 
parental genomic stability. Furthermore, when transplanted into infarcted mouse hearts, 9C-treated 
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fibroblasts differentiated into CMs and partially re-muscularized the injured area [7]. These results 
opened new insights for a completely drug-based direct reprogramming of human cells into CMs, 
even if many efforts are still needed to optimize these procedures before their possible use in 
clinical trials. 
The described chemical direct cardiac reprogramming strategies are summarized in Table 3. 
 
3. Considerations on Direct Cardiac Reprogramming 
Yamanaka’s revolutionary discovery of reprogramming somatic cells into iPSCs suggested the 
possibility to identify novel approaches to directly convert fibroblasts into functional 
cardiomyocytes without going through the pluripotent state (Figure 1). Despite an initial enthusiasm 
about the tremendous potential of direct reprogramming, there are many questions and technical 
challenges to be overcome before a real clinical application can be developed. The first concern 
regards the efficiency of the reprogramming process. The conversion rate of iCMs ranges from 5% 
to 20%, which is still too low to be sufficient for a full regeneration of an injured myocardium. In 
fact, as directly reprogrammed cells exit the cell cycle and stop proliferating, the initial 
reprogramming rate, as well as the speed and the quality of the conversion, have to be high enough 
to reach the cell numbers required for the development of a therapeutic strategy. It is estimated that 
at least 50% of the starting cells should be reprogrammed into mature CMs to be considered 
relevant in a post myocardial infarction state [9]. Moreover, another important concern is the fact 
that iCMs are still immature cells, rather distant from fully differentiated CMs. The percentage of 
functional iCMs, that are spontaneously beating and showing action potential, dramatically lowers 
to 0.01 - 0.1% [50]. Moreover, it was demonstrated that iCMs beat in vitro in a non-rhythmic way, 
typical feature of early embryonic CMs [50]. This point represents an important safety issue for 
future applications, because partially reprogrammed cells are not electrically coupled with cardiac 
resident cells, and could potentially generate disturbances of the physiological cardiac rhythm [50]. 
Another important aspect to be considered is the subtype of cardiomyocytes that are generated by 
direct reprogramming. Most of the transcription factors and small molecules combinations tested 
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generated only atrial-type cells [13, 21, 38, 40]. These results could represent a substantial 
limitation for the applicability of direct fibroblasts conversion strategies because the majority of 
cardiac cells lost during myocardial infarction that need replacement are of the ventricular subtype. 
However, it has been demonstrated that the GHMT strategy induced immature atrial, ventricular 
and pacemaker CMs in the same proportions [40]. Thus, in the future, it will be interesting to 
identify key factors for the determination of each different CMs subtype in order to apply specific 
direct reprogramming approaches to generate the correct cell type for each cardiac disease. 
Furthermore, several groups also tried to understand whether the reprogrammed cells passed 
through a pluripotent or progenitor state before becoming iCMs. This is an important aspect to be 
considered for a clinical application, because it would be preferable to generate CMs without 
inducing any pluripotent feature, in order to avoid the risks of teratomas formation and of excessive 
proliferation. Interestingly, direct fibroblasts conversion with transcription factors does not seem to 
depend on the pluripotent/progenitor state [16, 38, 40], whereas fibroblasts transdifferentiation with 
microRNAs passed rapidly through a progenitor state, as indicated by the upregulation of Mesp2, a 
cardiac mesodermal marker [25]. CASD approach, which employed pluripotency factors [13, 61], 
showed ISL1 positive cells mitotically active, but no OCT4, NANOG, or REX1 positive cells. The 
authors stated that no pluripotent intermediate was generated during the process [13, 61], despite 
another group, using the same protocol, observed NANOG positive cells during the differentiation 
process, indicating a transient acquisition of pluripotency [34]. Thus, it seems clear that a more 
accurate understanding of this aspect will be mandatory before any possible clinical application, in 
order to minimize the safety risks for the patients. Strictly connected with the pluripotent/progenitor 
state concern, another major obstacle for a future clinical translation of the direct reprogramming 
approach is the use of viruses carrying genetic material as the delivery method. Indeed, the risk of 
random genomic integration of overexpressed transgenes, that modify the genomic stability of the 
parental cells, could dramatically increase the probability of adverse effects and tumor formation [9, 
37]. Indeed, there is an urgent need to optimize the gene delivery systems with non-integrating 
vectors, or to replace the reprogramming transcription factors with small molecules cocktails. In 
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particular, small molecules seem to be really appealing because they offer numerous advantages as 
compared to virus-based approaches: they exert cellular effects in a transient and dose-dependent 
manner, and their action could be finely regulated. Moreover, they are non-immunogenic, cost-
effective, and could be structurally modified to improve potency, selectivity, or pharmacological 
properties [7]. In vitro experiments of both murine and human fibroblasts reprogrammed into iCMs 
[7, 17, 46] showed promising results, although the methods still need to be optimized to increase the 
conversion efficiency and to obtain iCMs with fully-mature cardiomyocytes characteristics. To 
date, there is no report of successful direct-chemical reprogramming of cardiac fibroblasts in vivo. 
This is probably due to several critical challenges of the approach, such as the development of 
specific delivery strategies of the reprogramming molecules in vivo. In particular, the ideal delivery 
system should allow the temporal and spatial control of compounds-release, in order to control the 
reprogramming process and, even more challenging, to direct the reprogramming molecules only to 
cardiac fibroblasts, to avoid undesired side-effects on other cells. 
Another interesting, yet puzzling result from these studies is that the reprogramming process seems 
to be more efficient in vivo than in vitro [26, 48, 51]. Indeed, cardiac microenvironment that 
provides soluble co-factors and extracellular matrix (ECM) connections in an organized 3D 
structure could play a crucial role, thereby facilitating a more rapid and efficient conversion of 
resident cells into more mature iCMs. Moreover, cardiac fibroblasts are exposed to mechanical 
forces inside the heart that might positively influence the reprogramming process [37]. Another 
aspect that may contribute to the increased efficiency in vivo could be associated to a self-
concentration of the virus in relatively small extracellular areas inside the heart, with consequent 
increased biological effects [9]. However, many critical points still remain pending, including the 
number of newly generated iCMs in vivo, which is difficult to be predicted and determined. The 
effect of reprogramming on the cardiac functionality principally depends on the efficiency of the 
conversion. Indeed, even if the efficiency is higher in vivo, it is commonly accepted that the number 
of iCMs is still too low to be responsible for the improvement detected in the cardiac function. A 
possible explanation could be that viral infection modifies the amount and the paracrine behavior of 
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the “scar-producing” fibroblasts, ultimately reducing the size of the scarring zone [38, 64]. In 
addition, the integration with the resident CMs is another critical point of the reprogramming 
strategies: newly formed iCMs have to integrate in the heart general structure and become 
electrically coupled with the native CMs. On the contrary, if iCMs remain isolated, they could have 
the propensity of triggering arrhythmic events, worsening an already compromised heart [49]. 
Therefore, the optimization of the in vivo reprogramming approach, in order to generate higher 
numbers of more mature iCMs is still an important goal to be achieved before a functional 
integrated myocardial tissue could be obtained. Moreover, from a clinical perspective, there is 
another very important aspect to be considered, which is the timing of intervention. The general 
principle of direct reprogramming is the notion that inducing the process, while the scar in the 
infarcted area is still forming, should give better results. However, it is still unclear how this would 
affect the healing process of the heart. The answer is difficult to predict, although it has been 
demonstrated that the absence of cardiac fibroblasts, due to loss of Tcf21 transcription factor, 
resulted in a complete perinatal lethality [2]. Moreover, the generation of ECM is fundamental for 
the maintenance of the 3D cardiac structure and its synthesis and degradation are highly dynamic 
processes regulated by fibroblasts [15]. Reduction of ECM production has been shown to be 
harmful for heart morphology, as it can cause CMs slippage, and a consequent chamber dilation and 
systolic dysfunction [43]. On the other hand, a reduction of fibroblasts in damaged areas will reduce 
local fibrosis, with positive effects for cardiac function [48]. However, it seems quite difficult to 
perfectly balance all different cell types present in a normal heart, using the current direct 
reprogramming strategies. 
Another important and critical point about the time of intervention is when the reprogramming 
should be performed. In fact, during the in vivo experiments, reprogramming factors are injected 
during ligation of the left anterior descending coronary [25, 48, 51]. However, this scenario is quite 
different from real life, as patients typically arrive to the hospital at least a few hours after an acute 
myocardial infarction. Furthermore, the earliest stages of healing, characterized by ECM synthesis, 
are fundamental in preventing cardiac rupture [11]. On the contrary, if the intervention occurs too 
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late, the ECM-rich environment may impair fibroblasts conversion and iCMs survival. Thus, it is 
clear that further studies are mandatory to better characterize these aspects for determining the best 
timing for intervention. 
 
4. Conclusions 
Despite decades of progress in modern medicine, heart disease is still one of the leading causes of 
death worldwide and there is essentially any cure for a failing heart. As heart failure is mainly 
characterized by loss and dysfunction of cardiomyocytes, efforts have been directed to identify 
strategies for replacing dead or damaged CMs with newly synthesized cardiac cells. As described in 
this review, direct cell reprogramming represents an attractive and valuable alternative to cell 
therapy, which may have several advantages over cell-transplantation strategies. Ideally, the process 
is simpler, does not require a surgical approach, and intrinsically should not have problems of 
immunogenicity or tumorigenesis. Nonetheless, although preliminary results are very promising, 
the reprogramming protocols still show many critical points that need to be addressed. 
However, the astonishing ongoing efforts worldwide are unprecedented, and it can be easily 
predicted that many answers will be provided in the nearest future, and that we are not very far from 
novel regenerative therapies. 
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Figure Legends  
Figure 1. Direct Reprogramming Approaches for Cardiac Regeneration 
Direct reprogramming of fibroblasts into iCMs was achieved with different strategies:  
Ex vivo approaches achieved by retro-/lentiviral infection of combinations of cardiac TFs or 
microRNAs; chemical reprogramming with proteins or small molecules cocktails; cell activation 
followed by chemical differentiation (CASD). iCMs were then intramyocardially injected in the 
failing heart.  
In situ lineage conversion of scar fibroblasts was induced directly by TFs or microRNAs 
intramyocardial delivery with retro-/lentiviral vectors.  
  24 
The small molecules approach has not been yet tested in vivo and could represent a future 
perspective to treat cardiac dysfunction. 
 
